Puma Biotechnology | PBYI - Gross Profit On Sales


Puma Biotechnology reported $20.32M in Gross Profit on Sales for its fiscal quarter ending in September of 2024.





Gross Profit On Sales Change Date
Agios Pharmaceuticals USD 52.86M 11.11M Sep/2026
Alnylam Pharmaceuticals USD 930.2M 62.49M Sep/2026
Amgen USD 8.46B 1.22B Sep/2026
Biogen USD 2.25B 127.8M Sep/2026
BioMarin Pharmaceutical USD 719.77M 6.35M Sep/2026
Daiichi Sankyo JPY 470.99B 20.54B Sep/2026
Exelixis USD 632.46M 24.43M Sep/2026
Gilead Sciences USD 6.73B 74M Sep/2026
Glaxosmithkline GBP 6.5B 743M Sep/2026
Incyte USD 1.45B 120.58M Sep/2026
MacroGenics USD 32.83M 21.59M Jun/2026
Moderna USD 995M 945M Sep/2026
Novartis USD 11.42B 180M Sep/2026
Pfizer USD 3.24B 3.49B Sep/2026
PTC Therapeutics USD 321.55M 19.05M Sep/2026
Puma Biotechnology USD 20.32M 24.85M Sep/2024
Regeneron Pharmaceuticals USD 3.71B 778.2M Jun/2026
Roche Holding CHF 22.69B 600M Jun/2026
Sangamo BioSciences -2.39M 1.09M Jun/2024
Sarepta Therapeutics USD 192.12M 59.03M Sep/2026
Takeda JPY 795B 18.22B Sep/2026
TG Therapeutics USD 199.14M 27.73M Jun/2026
Ultragenyx Pharmaceutical USD 141M 39M Sep/2026
Vanda Pharmaceuticals USD 50.6M 5.5M Dec/2024
Vertex Pharmaceuticals USD 2.94B 99.9M Sep/2026